Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.
$108.5MCash on Hand
19.9mo Cash Runway
Follow PMVP by emailGet an email when PMVP reports key news in an SEC filing, pushes back a promised milestone, files for a stock offering, lands on the Downside Radar or has an FDA decision. Free, no account needed.
We send one confirmation email first. Only emails about PMVP, unsubscribe in one click. Privacy
📣 What PMVP Says Is Next
first quarter of 2027 · “The Company anticipates submitting an NDA in the first quarter of 2027.”
Company press release, Aug 31, 2026 · SEC filing
fourth quarter of 2026 · “The Company plans to provide an update on all PYNNACLE Phase 2 pivotal trial cohorts at a medical conference in the fourth quarter of 2026, including the primary analysis data from the ovarian cancer cohort.”
Company press release, Aug 31, 2026 · SEC filing
first quarter of 2027 · “PMV Pharma anticipates submitting an NDA for accelerated approval of rezatapopt as a treatment for platinum-resistant/refractory ovarian cancer patients with a TP53 Y220C mutation in the first quarter of 2027.”
Company press release, Aug 14, 2026 · SEC filing
Quoted word for word from the company's press releases filed with the SEC. Timing is the company's own guidance, not a BioRadar estimate.
📄 Latest SEC Filings in Plain English
Nov 10, 2026 ·
Clinical trial Reported Q3 2026 results: $108.5 million in cash and securities as of September 30, 2026, with runway into Q1 2028 after a $50 million public offering. Net loss was $34.4 million and rezatapopt monotherapy interim ovarian cancer ORR was 46% (35/76), with NDA planned for Q1 2027. Form 8-K · SEC filing · Press release
Nov 10, 2026 ·
Quarterly report for the period ended Sep 30, 2026 Form 10-Q · SEC filing
Oct 5, 2026 ·
Leadership PMV Pharmaceuticals appointed Dr. Matthew Eckler, a Principal at Samsara BioCapital, to its board of directors effective October 1, 2026, with a term expiring at the 2029 annual meeting. He receives $40,000 in annual cash compensation plus an initial option for 84,000 shares. Form 8-K · SEC filing · Press release
Sep 2, 2026 ·
Financing Proposed a public offering of 22,055,000 shares of common stock, pre-funded warrants for up to 19,900,000 shares and common stock warrants for up to 41,955,000 shares. Form 424B5 · SEC filing
Sep 2, 2026 ·
Financing PMV Pharma priced an underwritten offering of 22,055,000 common shares and pre-funded warrants for 19,900,000 shares, plus accompanying warrants for 41,955,000 shares, at a combined $1.21 per share, with gross proceeds of about $50.8 million expected to close September 2, 2026. Form 8-K · SEC filing · Press release
Aug 31, 2026 ·
Clinical trial Updated interim ovarian cancer data from the PYNNACLE Phase 2 trial of rezatapopt showed a 46% ORR among 76 evaluable patients, with a median duration of response of 10.0 months. An NDA for accelerated approval is planned for Q1 2027. Form 8-K · SEC filing · Press release
Aug 31, 2026 ·
Financing Proposed offering of common stock, pre-funded warrants and accompanying common stock warrants, sold with five-year warrants. Warrant exercise price resets to as low as 33% of the initial price after an FDA NDA acceptance announcement for rezatapopt. Form 424B5 · SEC filing
Aug 31, 2026 ·
Financing PMV Pharmaceuticals terminated its at-the-market offering under a prospectus supplement dated November 27, 2024, which allowed sales of up to $113,792,846.40 of common stock through Jefferies. The company sold no shares under it. The sales agreement with Jefferies remains in effect. Form 424B3 · SEC filing
Each summary is written by AI from the filing itself, and one that names a number or a name the filing does not contain is not shown. Quarterly and annual reports are listed by period. Read the filing before acting on it.
🧪 Trial & FDA Catalysts
Dec 2026 · Phase 1/2 · Recruiting · The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE) Registry primary completion date, not a results date
Mar 2027 · Phase 1 · Recruiting · A Study to Investigate the Effects of Multiple Doses of Rezatapopt on the Pharmacokinetics of Metformin, Rosuvastatin, Repaglinide, and Midazolam in Patients With Advanced Solid Tumors Harboring a… Registry primary completion date, not a results date
Also used in these trials (approved or third-party drugs, not PMVP's own candidates): Pembrolizumab, Azacitidine, Famotidine, Itraconazole, Metformin Hydrochloride, Repaglinide.
Source: ClinicalTrials.gov trials sponsored by the company, one row per candidate at its most advanced registered trial. FDA approvals: Drugs@FDA. Wrong or missing drug? Report it
💰 Cash Runway & Dilution Risk
PMVP holds $108.5M in cash and short-term investments (as of Sep 30, 2026) and burns about $16.4M/quarter from operations,
an estimated runway of 19.9 months at that rate (BioRadar estimate, not company guidance).
Dilution pressure:62 · High
Cash runway 20 months +8
ATM program on file since Nov 2024 +15
Shelf registration (S-3, Nov 2024) +10
Going-concern doubt in the latest 10-Q +15Liquidity and Going Concern In connection with the issuance of its Quarterly Report on Form 10-Q for the quarter ended June 30, 2026 (the “Q2 2026 10-Q”), management determined that the Company’s then-available cash, cash equivalents, and marketable securities may not have been sufficient to fund its planned…10-Q, Nov 2026
Share count 75,534,742 (latest 10-Q/10-K). Insiders: each officer's, director's and 10% owner's latest Form 3, 4 or 5, direct and indirect shares; options are not counted. 5%+ holders: latest Schedule 13D or 13G of each holder above 5%. Institutions: the total held by all 13F filers (Yahoo Finance); the table lists the largest. Sources have different dates, so the split is approximate. Source: SEC EDGAR.
Get the full PMVP picture
The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for PMVP and every other ticker you follow. Card required, cancel anytime.
Data: SEC EDGAR, FDA, ClinicalTrials.gov, Yahoo Finance • Informational purposes only, not investment advice. • All tracked stocks A–Z
This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.